Rep. Lisa C. McClain Buys Kenvue Inc. (NYSE:KVUE) Stock

by · The Cerbat Gem

Representative Lisa C. McClain (R-Michigan) recently bought shares of Kenvue Inc. (NYSE:KVUE). In a filing disclosed on November 21st, the Representative disclosed that they had bought between $1,001 and $15,000 in Kenvue stock on October 30th. The trade occurred in the Representative’s “CHARLES SCHWAB 401K > SCHWAB 893” account.

Representative Lisa C. McClain also recently made the following trade(s):

  • Sold $1,001 – $15,000 in shares of Ciena (NYSE:CIEN) on 10/31/2025.
  • Sold $1,001 – $15,000 in shares of Alibaba Group (NYSE:BABA) on 10/31/2025.
  • Sold $1,001 – $15,000 in shares of Coherent (NYSE:COHR) on 10/31/2025.
  • Sold $1,001 – $15,000 in shares of Clorox (NYSE:CLX) on 10/31/2025.
  • Sold $1,001 – $15,000 in shares of Northern Trust (NASDAQ:NTRS) on 10/31/2025.
  • Sold $1,001 – $15,000 in shares of Honda Motor (NYSE:HMC) on 10/31/2025.
  • Sold $1,001 – $15,000 in shares of Home BancShares (NYSE:HOMB) on 10/31/2025.
  • Sold $1,001 – $15,000 in shares of Five Below (NASDAQ:FIVE) on 10/31/2025.
  • Sold $1,001 – $15,000 in shares of Pure Storage (NYSE:PSTG) on 10/31/2025.
  • Sold $1,001 – $15,000 in shares of BHP Group (NYSE:BHP) on 10/31/2025.

Kenvue Stock Up 1.1%

Shares of NYSE KVUE traded up $0.19 during mid-day trading on Thursday, reaching $17.22. 46,262,502 shares of the company traded hands, compared to its average volume of 54,833,996. The company’s fifty day moving average is $16.10 and its two-hundred day moving average is $19.65. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 0.98. Kenvue Inc. has a fifty-two week low of $14.02 and a fifty-two week high of $25.17. The stock has a market cap of $32.98 billion, a PE ratio of 22.95 and a beta of 0.71.

Kenvue (NYSE:KVUE – Get Free Report) last issued its quarterly earnings results on Monday, November 3rd. The company reported $0.28 EPS for the quarter, topping analysts’ consensus estimates of $0.27 by $0.01. The company had revenue of $3.76 billion during the quarter, compared to analyst estimates of $3.83 billion. Kenvue had a return on equity of 20.02% and a net margin of 9.55%.The company’s quarterly revenue was down 3.5% compared to the same quarter last year. During the same period in the previous year, the company earned $0.28 earnings per share. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. On average, analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, November 26th. Stockholders of record on Wednesday, November 12th were paid a dividend of $0.2075 per share. This represents a $0.83 annualized dividend and a dividend yield of 4.8%. The ex-dividend date was Wednesday, November 12th. Kenvue’s dividend payout ratio is 110.67%.

Analyst Ratings Changes

A number of research analysts have commented on the stock. UBS Group cut their price target on shares of Kenvue from $23.00 to $17.00 and set a “neutral” rating for the company in a research note on Wednesday, October 8th. Johnson Rice reissued a “neutral” rating on shares of Kenvue in a report on Tuesday, October 28th. Barclays boosted their target price on Kenvue from $17.00 to $18.00 and gave the stock an “equal weight” rating in a report on Monday, November 10th. The Goldman Sachs Group cut their target price on shares of Kenvue from $22.00 to $19.00 and set a “neutral” rating on the stock in a research report on Thursday, October 2nd. Finally, Bank of America dropped their price target on shares of Kenvue from $25.00 to $21.00 and set a “buy” rating for the company in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $20.23.

Read Our Latest Stock Report on Kenvue

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Renaissance Capital LLC lifted its holdings in shares of Kenvue by 8.3% in the 2nd quarter. Renaissance Capital LLC now owns 629,177 shares of the company’s stock worth $13,169,000 after acquiring an additional 48,267 shares during the last quarter. Farther Finance Advisors LLC grew its position in Kenvue by 80.7% during the 2nd quarter. Farther Finance Advisors LLC now owns 36,196 shares of the company’s stock worth $758,000 after acquiring an additional 16,164 shares during the last quarter. Arlington Partners LLC purchased a new position in Kenvue in the 2nd quarter worth approximately $2,110,000. Cornell Pochily Investment Advisors Inc. boosted its position in Kenvue by 144.6% during the 2nd quarter. Cornell Pochily Investment Advisors Inc. now owns 33,173 shares of the company’s stock valued at $694,000 after buying an additional 19,609 shares during the period. Finally, IFP Advisors Inc raised its position in Kenvue by 25.3% during the 1st quarter. IFP Advisors Inc now owns 15,278 shares of the company’s stock valued at $369,000 after purchasing an additional 3,081 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

About Representative McClain

Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan’s 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027.

McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan’s 9th Congressional District. She declared candidacy for the 2026 election.

Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor’s degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.

Kenvue Company Profile

(Get Free Report)

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.

See Also